Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AniCell BioTech is a regenerative medicine company focused on developing and commercializing amniotic tissue-based products for the veterinary market. The company specializes in treating orthopedic and soft tissue injuries in horses and dogs using non-invasive, allogeneic treatments derived from equine and canine amniotic material. Their product portfolio includes treatments for tendon and ligament repairs, wound healing, and ocular conditions, providing an alternative to traditional autologous stem cell therapies. AniCell's technology leverages the natural regenerative properties of amniotic tissues to accelerate healing and reduce inflammation without the need for surgical harvesting from the patient. The company's products are used by veterinarians to treat conditions such as osteoarthritis, suspensory ligament desmitis, and corneal ulcers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AniCell BioTech.